Clinical Trial: Inhaled Budesonide for Non-ventilated Infants at High Risk of Bronchopulmonary Dysplasia: the i-BUD Pilot Study

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional

Official Title: Evaluation of the Effectiveness of Inhaled Budesonide for Non-ventilated Infants at High Risk of Bronchopulmonary Dysplasia: the i-BUD Pilot Study

Brief Summary:

Bronchopulmonary dysplasia (BPD) is one of the most important morbidities of preterm infants with a high incidence and significant impact on resource utilization and long-term outcome. Systemic corticosteroids have been shown to be effective in the prevention of BPD through their potent anti-inflammatory effects but there are serious concerns on their potential detrimental effects on neurodevelopment of infants. In contrast, inhaled corticosteroids administered to ventilated infants are thought to be safer due to their topical effect but have not been shown to improve outcomes including BPD. To date, there have been few studies evaluating the effect of inhaled corticosteroids administered to non-ventilated infants for the prevention of BPD. Hence, we are conducting a double-blind randomized controlled pilot trial to examine the impact of inhaled budesonide on non-ventilated infants.

The study objectives, in a cohort of very preterm infants with signs of early BPD are: 1) to evaluate the effect of aerosolized budesonide on 'days on supplemental oxygen', and 2) to gain an estimate of the impact on BPD and 3) to assess the safety of the intervention in a small cohort of preterm infants.

This will be a single-center randomized double-blind controlled pilot trial. We will recruit a total of 50 infants born at less than 30 weeks gestation who are on continuous positive airway pressure (CPAP) with fraction of inspired oxygen ≥25% on day 14 of life or later. Inhaled budesonide 1mg (intervention group) or normal saline (placebo) will be administered three times a day until the infants do not need CPAP or supplemental oxygen or reach 36+0/7 weeks corrected gestational age. We will evaluate 'days on supplemental oxygen', BPD, re-intubation rates, days on mechanical ventilation and days on CPAP as well as adverse outcomes.

<

Detailed Summary:
Sponsor: Dr. Michael Dunn

Current Primary Outcome: Total days on supplemental oxygen from birth to discharge [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Bronchopulmonary dysplasia [ Time Frame: At 36+0/7 weeks corrected gestational age ]
    Bronchopulmonary dysplasia is defined as supplemental oxygen use at 36+0/7 weeks corrected gestational age
  • Mortality (all causes) [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 weeks ]
  • Death or bronchopulmonary dysplasia [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 weeks ]
  • Days on supplement oxygen after the study enrollment [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 weeks ]
  • Days on continuous positive airway pressure (CPAP) [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 weeks ]
    Support with continuous positive airway pressure, including use of biphasic CPAP and high flow nasal canula (>= 1L/minutes).
  • Days with significant apneas [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 weeks ]
    Significant apneas with more than 12 episodes requiring stimulation or more than one episode requiring mask-bagging in a six hour period
  • Culture proven sepsis [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 weeks ]
  • Gastrointestinal bleeding [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 weeks ]
  • Persistent hyperglycemia [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 weeks ]
    blood glucose > 10mmol/L more than twice in one day
  • Hypertension [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 weeks ]
    blood pressure ≥ 95th percentile for infant's gestational and postnatal ages
  • Salivary cortisol level [ Time Frame: 2 weeks after the study entry and at the first follow up visit at 6 week's corrected age ]
  • Postnatal growth [ Time Frame: at 36 weeks corrected gestational age and at first follow-up visit at 6 weeks' corrected age ]
    Weight, Head Circumference and Length
  • Patent ductus arteriosus [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 weeks ]
    PDA diagnosed clinically or by echocardiography


Original Secondary Outcome: Same as current

Information By: Sunnybrook Health Sciences Centre

Dates:
Date Received: June 25, 2013
Date Started: January 1, 2018
Date Completion: September 1, 2019
Last Updated: April 24, 2017
Last Verified: April 2017